[go: up one dir, main page]

AU2003258045A1 - Novel gamma-lactams as beta-secretase inhibitors - Google Patents

Novel gamma-lactams as beta-secretase inhibitors

Info

Publication number
AU2003258045A1
AU2003258045A1 AU2003258045A AU2003258045A AU2003258045A1 AU 2003258045 A1 AU2003258045 A1 AU 2003258045A1 AU 2003258045 A AU2003258045 A AU 2003258045A AU 2003258045 A AU2003258045 A AU 2003258045A AU 2003258045 A1 AU2003258045 A1 AU 2003258045A1
Authority
AU
Australia
Prior art keywords
lactams
beta
secretase inhibitors
novel gamma
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003258045A
Inventor
Andrew P. Combs
Carl P. Decicco
Andrew J. Tebben
Lorin A. Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2003258045A1 publication Critical patent/AU2003258045A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003258045A 2002-08-05 2003-08-05 Novel gamma-lactams as beta-secretase inhibitors Abandoned AU2003258045A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40139002P 2002-08-05 2002-08-05
US60/401,390 2002-08-05
PCT/US2003/024407 WO2004013098A1 (en) 2002-08-05 2003-08-05 Novel gamma-lactams as beta-secretase inhibitors

Publications (1)

Publication Number Publication Date
AU2003258045A1 true AU2003258045A1 (en) 2004-02-23

Family

ID=31495958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258045A Abandoned AU2003258045A1 (en) 2002-08-05 2003-08-05 Novel gamma-lactams as beta-secretase inhibitors

Country Status (4)

Country Link
US (1) US7557137B2 (en)
EP (1) EP1551801A4 (en)
AU (1) AU2003258045A1 (en)
WO (1) WO2004013098A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050609A1 (en) * 2002-11-27 2004-06-17 Elan Pharmaceutical, Inc. Substituted ureas and carbamates
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
JP2007523164A (en) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド Methods and compositions for intravenous administration of compounds related to proton pump inhibitors
US7388007B2 (en) 2004-08-26 2008-06-17 Bristol-Myers Squibb Company Gamma-lactams as beta-secretase inhibitors
MX2007003858A (en) * 2004-10-07 2007-12-11 Vitae Pharmaceuticals Inc Diaminoalkane aspartic protease inhibitors.
JP2008535863A (en) 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド Compounds that inhibit β-secretase activity and methods of use thereof
WO2007021793A1 (en) * 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
TWI411607B (en) * 2005-11-14 2013-10-11 Vitae Pharmaceuticals Inc Aspartic protease inhibitors
US7872028B2 (en) * 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
CL2007002689A1 (en) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc COMPOUNDS DERIVED FROM PIPERIDIN-1-CARBOXAMIDA, INHIBITORS OF THE RENINE; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS HYPERTENSION, CARDIAC INSUFFICIENCY, CARDIAC FIBROSIS, AMONG OTHERS.
ATE520690T1 (en) * 2006-09-18 2011-09-15 Vitae Pharmaceuticals Inc PIPERIDINE DERIVATIVES AS RENIN INHIBITORS
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US7902218B2 (en) 2006-12-12 2011-03-08 Bristol-Myers Squibb Company Substituted tetrahydroisoquinolines as β-secretase inhibitors
US7772221B2 (en) 2007-02-09 2010-08-10 Bristol-Meyers Squibb Company Diaminopropane derived macrocycles as inhibitors of β amyloid production
CN101668525A (en) 2007-03-01 2010-03-10 前体生物药物股份公司 New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
EP2167609A1 (en) * 2007-06-20 2010-03-31 Vitae Pharmaceuticals, Inc. Renin inhibitors
JP2011525488A (en) * 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Renin inhibitor and method of use thereof
US20110112145A1 (en) * 2008-06-26 2011-05-12 Nicole Marie Deschamps Salts Of Methyl 2-((R))-(3-Chlorophenyl)((R)-1-((S)-2-(Methylamino)-3((R)-tetrahydro-2H-Pyran-3-YL)Propylcarbamoyl)Piperidin-3-YL)Methoxy)Ethylcarbamate
ES2865504T3 (en) * 2008-10-16 2021-10-15 Univ Johns Hopkins Procedures and compositions for the improvement of cognitive function
AR077692A1 (en) * 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc SALTS OF 2 - ((R) - (3-CHLOROPHENYL) ((R) -1 - ((S) -2- (METHYLAMINE) -3 - ((R) -TETRAHYDRO-2H-PIRAN-3-IL) PROPILCARBAMOIL ) PIPERIDIN -3-IL) METOXI) METHYL ETILCARBAMATE
ES2548913T3 (en) 2009-09-11 2015-10-21 Probiodrug Ag Heterocyclic derivatives such as glutaminyl cyclase inhibitors
EA037187B1 (en) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Method and composition for treating a cognitive disorder
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
CA2789440C (en) 2010-03-10 2020-03-24 Probiodrug Ag Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (en) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド Methods and compositions for improving cognitive function
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
US12071396B2 (en) * 2019-03-15 2024-08-27 Chugai Seiyaku Kabushiki Kaisha Method for preparing aromatic amino acid derivative
CN115197161B (en) * 2022-08-18 2024-01-26 成都大学 Z-configuration allyl amino acid derivative, preparation method and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705846A (en) 1986-03-27 1987-11-10 The Upjohn Company Novel renin inhibiting peptides having a gamma lactam pseudo dipeptide insert
IL92011A0 (en) 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
US5120718A (en) 1991-06-13 1992-06-09 Abbott Laboratories Candida acid protease inhibiting compounds
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors
WO1997016425A1 (en) 1995-10-30 1997-05-09 Merck & Co., Inc. Novel inhibitors of peptide binding to mhc class ii proteins
US5719296A (en) 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
JP2003502342A (en) * 1999-06-15 2003-01-21 エラン ファーマスーティカルズ インコーポレイテッド Statin-induced tetrapeptide inhibitors of beta-secretase
WO2001007407A1 (en) 1999-07-26 2001-02-01 Bristol-Myers Squibb Pharma Company Lactam inhibitors of hepatitis c virus ns3 protease
ATE343562T1 (en) * 2000-03-23 2006-11-15 Elan Pharm Inc COMPOUNDS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
EP1299352B1 (en) * 2000-06-30 2005-12-28 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
US6696488B2 (en) * 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production

Also Published As

Publication number Publication date
WO2004013098A1 (en) 2004-02-12
US7557137B2 (en) 2009-07-07
US20070265331A1 (en) 2007-11-15
EP1551801A4 (en) 2007-06-20
EP1551801A1 (en) 2005-07-13

Similar Documents

Publication Publication Date Title
AU2003258045A1 (en) Novel gamma-lactams as beta-secretase inhibitors
AU2003202263A1 (en) Roh-kinase inhibitors
AU2003255376A1 (en) Piperidine-derivatives as pde4 inhibitors
AU2003301302A1 (en) Pyradazine compounds as gsk-3 inhibitors
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
AU2003281351A1 (en) Substituted 3-cyanoquinolines as mek inhibitors
AU2003271566A1 (en) Pyrrolopyrazines as kinase inhibitors
AU2003266949A1 (en) Compounds
AU2003221098A1 (en) Oligofluorenylene compounds
AU2003279366A1 (en) Novel compounds
AU2003249683A1 (en) Nf-:b inhibitors
AU2003212310A1 (en) (4,2-disubstituted-thiazol-5-yl)amine compounds as pde7 inhibitors
AU2003230392A1 (en) Beta-secretase inhibitors
AU2003215635A1 (en) Thiazol-2-yl-imine compounds as pde-7 inhibitors
IL164898A0 (en) Heterotricyclyl 6-alkylidene-penems as beta-lactamase inhibitors
AU2003234925A1 (en) TGF-Alpha EXPRESSION INHIBITORS
AU2003216859A1 (en) Amidoacetonitrile compounds
AU2003280578A1 (en) Heterocyclic compounds
AU2003242559A1 (en) Alkylaminosiloxanes as corrosion inhibitors
AU2003210671A1 (en) Nek2 inhibitors
AU2003232362A1 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003251259A1 (en) Novel compounds
AU2003292667A1 (en) Benzocycloheptapyridine compounds
AU2003255322A1 (en) Compounds
AU2003275480A1 (en) Compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase